1 |
Hu SP, Ge MX, Gao L, Jiang M, Hu KW. LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis. Cancer Cell Int 2021;21:686. [PMID: 34923990 DOI: 10.1186/s12935-021-02404-x] [Reference Citation Analysis]
|
2 |
Tu C, Yang K, Wan L, He J, Qi L, Wang W, Lu Q, Li Z. The crosstalk between lncRNAs and the Hippo signalling pathway in cancer progression. Cell Prolif 2020;53:e12887. [PMID: 32779318 DOI: 10.1111/cpr.12887] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
|
3 |
Yao J, Wang C, Dong X, Zhang Y, Li Y, Zhou H, Zhang L. lncRNA SNHG22 sponges miR‑128‑3p to promote the progression of colorectal cancer by upregulating E2F3. Int J Oncol 2021;59:71. [PMID: 34368861 DOI: 10.3892/ijo.2021.5251] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Chen W, Li Y, Guo L, Zhang C, Tang S. Long non-coding RNA FTX predicts a poor prognosis of human cancers: a meta-analysis. Biosci Rep 2021;41:BSR20203995. [PMID: 33398336 DOI: 10.1042/BSR20203995] [Reference Citation Analysis]
|